IOL Chemicals Q1 FY27 Earnings Call — Analysis (NSE: IOLCP)
Strong Q1 FY27 with 37% revenue growth and 60% EBITDA jump driven by non-ibuprofen API scaling, capacity utilization, and export expansion.
Result quality: stable — Steady quarter. Management sentiment: optimistic.
The take
Q1FY27 Revenue ₹756 Cr ( +37% YoY ) . New guidance — FY27 iol consolidated revenue 15% to 20% . New story: Non-ibuprofen API diversification .
Results
Revenue ₹756 Cr +37% YoY; EBITDA ₹111 Cr +60.7% YoY, margin 14.6% (+2.2ppts); PAT ₹64.5 Cr +89.9% YoY.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Revenue | ₹756 Cr | +37% | yoy · Q1FY27 |
| EBITDA | ₹111 Cr | +60.7% | yoy · Q1FY27 |
| EBITDA margin | 14.6% | +2.2% pts | yoy · Q1FY27 · vs 12.4% |
| PAT | ₹64.5 Cr | +89.9% | yoy · Q1FY27 |
| PAT margin | 8.4% | +2.3% pts | yoy · Q1FY27 · vs 6.1% |
| Export revenue share | 28.5% | +4.1% pts | yoy · Q1FY27 · vs 24.4% |
| Non-ibuprofen pharma revenue share | 43% | +7% pts | yoy · Q1FY27 · vs 36% |
Guidance
FY27 revenue growth 15-20%, EBITDA margin 14-15%, export share ~25-30%; aspirational FY28 EBITDA margin 15-17%.
What management committed to
- IOL expects consolidated revenue growth of 15% to 20% in FY27. — 15% to 20%, FY27
- IOL expects EBITDA margin in the range of 14% to 15% for FY27. — 14% to 15%, FY27
- Export contribution to revenue is expected to be approximately 25% to 30% in FY27. — 25% to 30%, FY27
- Paracetamol capacity utilization is expected to reach around 70% by the end of FY27, from ~55% currently at the enhanced 10,800 MTPA capacity. — around 70%, FY27
- Management targets non-ibuprofen products to contribute around 50% of pharmaceutical revenue in the mid-to-short term. — around 50%, mid to short term
- By FY29, the non-ibuprofen segment is expected to contribute around 50% to 55% of API segment revenue. — 50% to 55%, FY29
- IOL has an aspirational plan for EBITDA margin of 15% to 17% in FY28, subject to market conditions. — 15% to 17%, FY28
- Annual capex will be approximately ₹200 Cr, with ~60% directed to expansion/new products and 40% to infrastructure/improvements. — ₹200 Cr, 60:40 split, annually
- No major project on the 101-acre greenfield land parcel will be commissioned in FY27. — FY27
- The new Triacetin plant has a steady-state revenue potential of around ₹120 Cr per year. — ₹120 Cr per year
Key themes
Non-ibuprofen diversification and export-led growth
How the narrative shifted
- Non-ibuprofen API diversification: Management positions IOL as a diversified API platform, highlighting that non-ibuprofen revenue grew 67% YoY and now contributes 43% of pharma revenue, with a clear path to 50%.
- Export market expansion: Exports reached 28.5% of revenue with new China NMPA approval for clopidogrel; management targets 25-30% share for FY27, leveraging regulatory approvals and customer agreements.
- Capacity utilization and operating leverage: Most API assets at 80-95% utilization; paracetamol ramp-up from 55% to 70% by year-end is a key margin lever. Management attributes margin improvement primarily to internal efficiencies.
- Input cost volatility and price stability: Raw material prices spiked due to US-Iran conflict but have since stabilized; management expects ethyl acetate and acetic anhydride margins to remain constant going forward.
- Disciplined capex and future growth platform: Annual capex of ~₹200 Cr split 60:40 between expansion and infrastructure; greenfield land parcel being prepared with statutory approvals, but no major commissioning this fiscal.
- Chemical segment resilience: Chemical business delivered improved margins, aided by higher exports and capacity enhancements; Triacetin adds a new product line with ~₹120 Cr revenue potential.
- Regulatory progress in China: NMPA China approval for clopidogrel represents a new regulated-market access point, supplementing existing CEP and US FDA filings across the portfolio.
Operational commentary
- Non-ibuprofen API revenue grew 67% YoY, reaching 43% of pharmaceutical revenue (vs 36% in Q1FY26); on track toward 50% target.
- Exports rose to 28.5% of total revenue; NMPA (China) approval received for clopidogrel, expanding regulated-market reach.
- Paracetamol capacity enhanced to 10,800 MTPA, currently operating at ~55% utilization, expected to reach ~70% by end-FY27.
- Most other API assets operating at 80-95% utilization, supporting broad-based pharma growth.
- New Triacetin plant commenced production in May 2026; revenue potential ~₹120 Cr per annum at steady state.
- Annual capex run-rate ~₹200 Cr, with ~60% directed to expansion/new products and 40% to infrastructure/improvements.
- Chemical segment maintained strong margins and increased exports; capacity enhancements completed for ethyl acetate and acetic anhydride.
- R&D investment includes acquisition of high-end analytical instruments (XRD, LCMS, GCMS) for stringent impurity profiling.
Analyst Q&A
Q. What is the split of pharma growth between volume and realization?
Management declined to provide exact numbers, stating the detail is not shared on calls; growth mostly from capacity utilization and better operational efficiency.
Q. Did IOL beat SMS Pharma in ibuprofen manufacturing technology this quarter?
Declined to comment on competitors, focusing solely on IOL's own strategy and capabilities.
Q. Could the current strong demand sustain for the next 8-12 quarters?
Management sees FY27 growth as sustainable based on order book visibility but cautioned that FY28 guidance cannot be predicted now; 15-17% EBITDA margin is an aspirational plan subject to market scenario.
Q. Was Q1 profitability partly driven by one-time inventory gains from commodity price spikes?
Management denied material inventory gains in Q1, attributing performance to capacity utilization, product mix, operational efficiencies, and non-ibu exports.
Research and educational content only. Not investment advice.